Please Enable Cookies

www.cablinginstall.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation process is complete.

Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Purple Biotech Ltd ADR (NQ: PPBT )

0.4070 -0.0306 (-6.99%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jun 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Purple Biotech Ltd ADR

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Fortifies NT219 Patent Protection
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces Closing of $5 Million Registered Direct Offering
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces $5 Million Registered Direct Offering
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reports Second Quarter 2023 Financial Results
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Debuts Scientific Advisory Board
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation Study
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Expands Pipeline of First-in-Class Therapeutics with Acquisition of Immunorizon and Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech and Mor Research Applications Announce Research Collaboration to Identify Promising Investigational Oncology Treatments
As a subsidiary of Clalit Healthcare Services, Israel’s largest HMO, Mor Research Applications brings Purple Biotech first access to research conducted at 14 hospitals The collaboration with Mor... 
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech to Present at the Jefferies London Healthcare Conference
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Appoints Lior Fhima as Chief Financial Officer
From Purple Biotech Ltd.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.